---
title: "Kingchem released its first-quarter performance, with a net profit attributable to the parent company of 47.4178 million yuan, a year-on-year increase of 183.24%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237122933.md"
description: "Kingchem released its Q1 2025 performance, with operating revenue of 176 million yuan, a year-on-year increase of 41.83%; net profit attributable to the parent company of 47.4178 million yuan, a year-on-year increase of 183.24%; net profit excluding non-recurring gains and losses of 42.5534 million yuan, a year-on-year increase of 171.28%; basic earnings per share of 0.39 yuan/share"
datetime: "2025-04-23T08:44:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237122933.md)
  - [en](https://longbridge.com/en/news/237122933.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237122933.md)
generator: "portal-rs"
---

# Kingchem released its first-quarter performance, with a net profit attributable to the parent company of 47.4178 million yuan, a year-on-year increase of 183.24%

According to the Zhitong Finance APP, Kingchem (301509.SZ) released its first-quarter report for 2025, showing an operating income of 176 million yuan, a year-on-year increase of 41.83%; net profit attributable to shareholders of the listed company was 47.4178 million yuan, a year-on-year increase of 183.24%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 42.5534 million yuan, a year-on-year increase of 171.28%; basic earnings per share were 0.39 yuan/share

### Related Stocks

- [301509.CN](https://longbridge.com/en/quote/301509.CN.md)

## Related News & Research

- [Chinese Pharma Companies Plan Hong Kong Listings](https://longbridge.com/en/news/297979501.md)
- [BioGaia (OM:BIOG B) Could Be 26% Undervalued Following Its Recordati Deal](https://longbridge.com/en/news/298111133.md)
- [DAZN partners with SENSHI to stream kickboxing events worldwide for free](https://longbridge.com/en/news/298082089.md)
- [UBL: Premiumization and regulatory reforms fuel strong growth and margin expansion ambitions](https://longbridge.com/en/news/297872232.md)
- [Orum to begin Phase I trial of ORM-1153 after FDA clearance](https://longbridge.com/en/news/298030380.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**